«Ульяновский медико-биологический журнал»

CLINICAL MEDICINE

Download article

DOI 10.34014/2227-1848-2021-4-73-88

 

AUTONOMIC NERVOUS SYSTEM DYSFUNCTION IN BREAST CANCER PATIENTS

Yu.D. Udalov1, L.A. Belova2, V.V. Mashin2, L.A. Danilova1, A.A. Kuvayskaya2

1 Federal Scientific Clinical Centre for Medical Radiology and Oncology, Dimitrovgrad, Russia;

2 Ulyanovsk State University, Ulyanovsk, Russia

 

When studying oncology diseases, it is necessary not only to assess their nature, progress and outcome depending on the local disease process, but also to take into account overall health, since multiple organ damage has a prognostic value and determines the disease outcome. All mechanisms and structures that have an integrative and homeostatic effect on the overall health should be considered. One of these structures is the autonomic nervous system.

Traditionally, the autonomic nervous system has been considered in terms of 3 components: sympathetic, parasympathetic and intestinal. However, in recent years, ideas about neuroendocrine and neuroimmune systems have come to the fore, justifying the expansion of the concept "autonomy of the nervous system." In case of autonomous dysfunction, dysregulation of the involuntary body functions occurs, and autonomic neuropathy develops. There are cardiovascular, gastrointestinal, urogenital, and sudomotor forms of autonomic neuropathy, which are characterized by certain changes in various pathological states, especially in malignant processes. We pay attention to breast cancer, which ranks first in the structure of oncology diseases in the Russian Federation.

Nowadays, there are only a few studies devoted to the changes in the autonomic nervous system in patients with breast cancer during anticancer drug therapy, taking into account the disease progress and clinical features, as well as methods for dysfunction remodeling.

The article analyzes a number of scientific information sources that can help to study various forms of autonomic neuropathy in patients with breast cancer and allow assessing the use of medical rehabilitation for such patients.

Key words: autonomic nervous system, autonomic neuropathy, breast cancer, antitumor drug therapy.

Conflict of interest. The authors declare no conflict of interest.

 

References

  1. Erica A. Wehrwein, Hakan S. Orer, Susan M. Barman. Overview of the Anatomy, Physiology, and Pharmacology of the Autonomic Nervous System. Comprehensive Physiology. 2016; 6 (3): 1239–1278. DOI: 10.1002/cphy.c150037.

  2. Goldstein D.S. The extended autonomic system, dyshomeostasis, and COVID-19. Clinical autonomic research: official journal of the Clinical Autonomic Research Society. 2020; 30 (4): 299–315.

  3. Dineen J., Freeman R. Autonomic Neuropathy. Seminars in neurology. 2015; 35 (4): 458–468. DOI: 10.1055/s-0035-1558983.

  4. Dedov I.I., Shestakova M.V., Mayorov A.Yu. Algoritmy spetsializirovannoy meditsinskoy pomoshchi bol'nym sakharnym diabetom. Vyp. 9 (dop.) [Algorithms for specialized medical care for patients with diabetes mellitus]. Sakharnyy diabet. 2019; 22 (S1): 104–106. DOI: 10.14341/DM221S1 (in Russian).

  5. Koual M., Tomkiewicz С., Cano-Sancho German, Antignac Jean-Philippe, Bats Anne-Sophie, Coumoul X. Environmental chemicals, breast cancer progression and drug resistance. Environ. Health. 2020; 19 (1): 117. DOI: 10.1186/s12940-020-00670-2.

  6. Ageeva L.I., Aleksandrova G.A., Zaychenko N.M. Zdravookhranenie v Rossii [Healthcare in Russia]. 2019: stat. sb. Moscow; 2019 (in Russian).

  7. Kaprin A.D., Starinskiy V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2018 godu (zabolevaemost' i smertnost') [Malignant neoplasms in Russia in 2018 (morbidity and mortality)]. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii; 2019 (in Russian).

  8. Kaprin A.D., Starinskiy V.V., Petrova G.V. Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2018 godu (zabolevaemost' i smertnost') [Cancer care for the Russia population in 2018 (morbidity and mortality).]. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii; 2019 (in Russian).

  9. Susan G. Lakoski, Lee W. Jones, Ronald J. Krone, Phyllis K. Stein, Jessica M. Scott. Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. American heart journal. 2015; 170 (2): 231–241. DOI: 10.1016/j.ahj.2015.05.014.

  10. Guy Jerusalem, Patrizio Lancellotti, Sung-Bae Kim. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast cancer research and treatment. 2019; 177 (2): 237–250. DOI: 10.1007/s10549-019-05303-y.

  11. Rodrigo Carrasco, Rodrigo L Castillo, Juan G Gormaz, Montserrat Carrillo, Paaladinesh Thavendiranathan. Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies. Oxidative medicine and cellular longevity. 2021; 2021: 1–2. DOI: 10.1155/2021/8863789.

  12. Adão R.G. de Keulenaer, Leite-Moreira A., Brás-Silva C. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention. Revista Portuguesa de Cardiologia. 2013; 32 (5): 395–409. DOI: 10.1016/j.repc.2012.11.002.

  13. Emanuela Salvatorelli, Pierantonio Menna, Massimo Chello, Elvio Covino, Giorgio Minotti. Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites. Journal of Pharmacology and Experimental Therapeutics. 2018; 364 (2): 323–331. DOI: 10.1124/jpet.117.246140.

  14. Lakoski S.G., Jones L.W., Krone R.J., Stein P.K., Scott J.M. Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. American heart journal. 2015; 170 (2): 231–241.

  15. Kirkham А.A, Lloyd M.G., Claydon V.E, Gelmon K.A., McKenzie D.C., Campbell K.L. Longitudinal Study of the Association of Clinical Indices of Cardiovascular Autonomic Function with Breast Cancer Treatment and Exercise Training. The Oncologist. 2019; 24 (2): 273–284. DOI: 10.1634/theoncologist.2018-0049.

  16. Peter A. Henriksen. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart (British Cardiac Society). 2018; 104 (12): 971–977. DOI: 10.1136/heartjnl-2017-312103.

  17. Jones L.W., Courneya K.S., Mackey J.R., Muss H.B., Pituskin E.N., Scott J.M., Hornsby W.E., Coan A.D., Herndon 2nd J.E., Douglas P.S., Haykowsky M. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. Journal of clinical oncology. 2012; 30 (20): 2530–2537. DOI: 10.1200/JCO.2011.39.9014.

  18. Kluser Sales A.R., Negrão M.V., Testa L., Ferreira-Santos L., Ramalho Groehs R.V., Carvalho B., Toschi-Dias E., Rocha N.G., Martins Laurindo F.R., Debbas V., Rondon M.U.PB., Mano M.S., Hajjar L.A., Gehm Hoff P.M., Filho R.K., Negrão C.E. Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer. American journal of physiology. Heart and circulatory physiology. 2019; 317 (7): 1–12. DOI: 10.1152/ajpheart.00756.2018.

  19. Sarita Lígia Pessoa de Melo Machado Guimarães, Simone Cristina Soares Brandão, Luciana Raposo Andradе, Rafael José Coelho Maia, Brivaldo Markman Filho. Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity. Arquivos Brasileiros de Cardiologia. 2015; 105 (3): 228–34. DOI: 10.5935/abc.20150075.

  20. Akarachkova E.S., Baydauletova A.I., Belyaev A.A., Blinov D.V., Gromova O.A., Dulaeva M.S., Zamergrad M.V, Isaykin A.I., Kadyrova L.R., Klimenko A.A., Kondrashov A.A., Kosivtsova O.V., Kotova O.V., Lebedeva D.I., Medvedev V.E., Orlova A.S., Travnikova E.V., Yakovlev O.N. Stress: prichiny i posledstviya, lechenie i profilaktika. Klinicheskie rekomendatsii [Stress: causes and effects, treatment and prevention. Clinical guidelines]. St. Petersburg: Skifiya-print; Moscow: Profmedpress; 2020 (in Russian).

  21. Kiseleva M.G. Psikhologicheskie faktory i techenie serdechno-sosudistykh zabolevaniy [Psychological factors and cardiovascular disease progression]. Nauchnyy psikhologicheskiy zhurnal. 2012; 1 (7): 124–130 (in Russian).

  22. Zikiryakhodzhaev A.D., Ermoshchenkova M.V., Sirota N.A., Fetisov B.A. Psikhologicheskie aspekty bol'nykh rakom molochnoy zhelezy v zavisimosti ot nalichiya vidimogo posleoperatsionnogo defekta [Psychological aspects of breast cancer patients depending on a visible postoperative defect]. Issledovaniya i praktika v meditsine. 2015; 2 (2): 85–91. DOI: 10.17709/2409-2231-2015-2-2-85-91 (in Russian).

  23. Udalov Yu.D., Gordienko A.V., Samoylov A.S., Bakharev S.A. Prognozirovanie i minimizatsiya riskov fatal'nykh iskhodov planovogo khirurgicheskogo lecheniya onkologicheskikh bol'nykh s komorbidnoy somaticheskoy patologiey [Lethality risk prediction and minimization in planned surgical treatment of cancer patients with comorbid somatic pathology]. Meditsina ekstremal'nykh situatsiy. 2018; 20 (2): 136–145 (in Russian).

  24. Kolotik-Kameneva O.Yu., Belova L.A., Mashin V.V. Emotsional'no-volevye narusheniya kak rezul'tat tserebral'nogo sosudistogo remodelirovaniya pri gipertonicheskoy bolezni [Emotional and volitional disorders as a result of cerebral vascular remodeling in hypertension]. Ul'yanovskiy mediko-biologicheskiy zhurnal. 2015; 4: 54–57 (in Russian).

  25. Snegovoy A.V., Davydov M.I. Sovremennye vozmozhnosti podderzhivayushchey terapii lekarstvennogo protivoopukholevogo lecheniya [Modern possibilities of supportive therapy for drug anticancer treatment]. Vestnik FGBU «RONTs im. N.N. Blokhina». 2016; 27 (2): 5–16 (in Russian).

  26. Titova Zh.V., Bodienkova G.M. Rol' tsitokinovoy seti v mekhanizmakh neyroimmunnogo vzaimodeystviya (obzor literatury) [The role of cytokine network in the mechanisms of neuroimmune interaction (literature review)]. Byulleten' VSNTs SO RAMN. 2013; 2–1 (90): 171–175 (in Russian).

  27. Haworth K.B., Leddon J.L., Chen C.Y., Horwitz E.M., Mackall C.L., Cripe T.P. Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr. Blood Cancer. 2015; 62 (4): 571–576. DOI: 10.1002/pbc.25359.

  28. Quezada S.A., Peggs K.S. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. British journal of Сancer. 2013; 108 (8): 1560–1565. DOI: 10.1038/bjc.2013.117.

  29. Mittendorf E., Philips A., Meric-Bernstam F., Qiao N., Wu Y., Harrington S., Su X., Wang Y., Gonzalez-Angulo A.M., Akcakanat A., Chawla A., Curran M., Hwu P., Sharma P., Litton J.K., Molldrem J.J., Alatrash G. PD-L1 expression in triple negative breast cancer. Cancer immunology research. 2014; 2: 361–370.

  30. Denkert C., Liedtke C., Tutt A., von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017; 389 (10087): 2430–2442. DOI: 10.1016/S0140-6736(16)32454-0.

  31. Gobbini E., Ezzalfani M., Dieras V., Bachelot T., Brain E., Debled M., Jacot W., Mouret-Reynier M.A., Goncalves A., Dalenc F., Patsouris A., Ferrero J.M., Levy C., Lorgis V., Vanlemmens L., Lefeuvre-Plesse C., Mathoulin-Pelissier S., Petit T., Uwer L., Jouannaud C., Leheurteur M., Lacroix-Triki M., Cleaud A.L., Robain M., Courtinard C., Cailliot C., Perol D., Delaloge S. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European journal of cancer. 2018; 96: 17–24. DOI: 10.1016/j.ejca.2018.03.015.

  32. Irwin M.R., Cole S.W. Reciprocal regulation of the neural and innate immune systems. Nature Reviews Immunology. 2011; 11: 625–632.

  33. Howard-Anderson J., Ganz P.A., Bower J.E., Stanton A.L. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. Journal of the National Cancer Institute. 2012; 104: 386–405.

  34. Alexandra D. Crosswell, Kimberly G. Lockwood, Patricia A. Ganz, Bower J.E. Low heart rate variability and cancer-related fatigue in breast cancer survivors. Psychoneuroendocrinology. 2014; 45: 58–66. DOI: 10.1016/j.psyneuen.2014.03.011.

  35. Allison Soucise, Caila Vaughn, Cheryl L. Thompson. Sleep quality, duration, and breast cancer aggressiveness. Breast cancer research and treatment. 2017; 164 (1): 169–178. DOI: 10.1007/s10549-017-4245-1.

  36. Otte J.L., Davis L., Carpenter J.S., Krier C., Skaar T.C., Rand K.L., Weaver M., Landis C., Chernyak Y., Manchanda S. Sleep disorders in breast cancer survivors. Supportive care in cancer. 2016; 24: 4197–4205. DOI: 10.1007/s00520-016-3247-6.

  37. Otte J.L., Carpenter J.S., Russell K.M., Bigatti S., Champion V.L. Prevalence, severity, and correlates of sleep-wake disturbances in long-term breast cancer survivors. Journal of pain and symptom management. 2010; 39 (3): 535–547. DOI: 10.1016/j.jpainsymman.2009.07.004.

  38. Borniger J.C. Central Regulation of Breast Cancer Growth and Metastasis. Journal of cancer metastasis and treatment. 2019; 5: 23. DOI: 10.20517/2394-4722.2018.107.

  39. Hanahan D., Weinberg R.A. Hallmarks of Cancer: The Next Generation. Journal of cancer metastasis and treatment. 2011; 144: 646–674. DOI: 10.1016/j.cell.2011.02.013.

  40. Palesh O.G., Roscoe J.A., Mustian K.M., Roth T., Savard J., Ancoli-Israel S., Heckler C., Purnell J.Q., Janelsins M.C., Morrow G.R. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. Journal of Сlinical Оncology. 2010; 28 (2): 292–298. DOI: 10.1200/JCO.2009.22.5011.

  41. Palesh O., Aldridge-Gerry A., Zeitzer J.M., Koopman C., Neri E., Giese-Davis J., Jo B., Kraemer H., Nouriani B., Spiegel D. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep. 2014; 37 (5): 837–842. DOI: 10.5665/sleep.3642.

  42. Bower J.E., Ganz P.A., Irwin M.R., Kwan L., Breen E.C., Cole S.W. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? Journal of Сlinical Оncology. 2011; 29 (26): 3517–3522. DOI: 10.1200/JCO.2011.36.1154.

  43. Bower J.E., Lamkin D.M. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain, behavior, and immunity. 2013; 30 Suppl. (0): 48–57. DOI: 10.1016/ j.bbi.2012.06.011.

  44. Liu L., Mills P.J., Rissling M., Fiorentino L., Natarajan L., Dimsdale J.E., Sadler G.R., Parker B.A., Ancoli-Israe S. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain, behavior, and immunity. 2012; 26 (5): 706–713. DOI: 10.1016/j.bbi.2012.02.001.

  45. Krueger J.M., Frank M.G., Wisor J.P., Roy S. Review Sleep function: Toward elucidating an enigma. Sleep Medicine Reviews. 2016; 28: 46–54. DOI: 10.1016/j.smrv.2015.08.005.

  46. Schmidt E.M., Linz B., Diekelmann S., Besedovsky L., Lange T., Born J. Effects of an interleukin-1 receptor antagonist on human sleep, sleep-associated memory consolidation, and blood monocytes. Brain, behavior, and immunity. 2015; 47: 178–185. DOI: 10.1016/j.bbi.2014.11.012.

  47. Savard J., Ivers H., Villa J., Caplette-Gingras A., Morin C.M. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. Journal of Сlinical Оncology. 2011; 29 (26): 3580–3586. DOI: 10.1200/JCO.2010.33.2247. 

  48. Scott J.M., Jones L.W., Hornsby W.E., Koelwyn G.J., Khouri M.G., Joy A.A., Douglas P.S., Lakoski S.G. Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training. International Journal of Сardiology. 2014; 171 (2).

  49. Udalov Yu.D., Belova L.A., Mashin V.V., Stepanyuchenko E.M., Danilova L.A., Ayzatullin I.F., Kuvayskaya A.A. Metodicheskie osnovy onkoreabilitatsii na baze FGBU FNKTsRiO FMBA Rossii. Metodicheskie rekomendatsii [Methodological bases for oncological rehabilitation in Federal scientific clinical centre for medical radiology and oncology. Guidelines]. Moscow; 2021: 26–56 (in Russian).

  50. Lakoski S.G., Jones L.W., Krone R.J., Stein P.K., Scott J.M. Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. American heart journal. 2015; 170: 231–241.

  51. Niederer D., Vogt L., Thiel C., Schmidt K., Bernhörster M., Lungwitz A., Jäger E., Banzer W. Exercise effects on HRV in cancer patients. International Journal of Sports Medicine. 2013; 34: 68–73.

  52. Hyeng-Cheol Shin, Jung-Ok Yang, Seung-Ryol Kim. Effects of circuit exercise on autonomic nerve system of survivors after surgery of breast cancer. Journal of physical therapy science. 2016; 28 (10): 2898–2903. DOI: 10.1589/jpts.28.2898.

  53. Toohey K., Pumpa К., McKune A., Cooke J., Welvaert M., Northey J., Quinlan C., Semple S. The impact of high-intensity interval training exercise on breast cancer survivors: a pilot study to explore fitness, cardiac regulation and biomarkers of the stress systems. BMC Cancer. 2020; 20 (1): 787. DOI: 10.1186/s12885-020-07295-1

  54. Palesh O., Aldridge-Gerry A., Zeitzer J.M., Koopman C., Neri E., Giese-Davis J., Jo B., Kraemer H., Nouriani B., Spiegel D. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep. 2014; 37 (5): 837–842. DOI: 10.5665/sleep.3642

  55. Shu-Chuan Chen, Ming-Lee Yeh, Hsiu-Ju Chang, Mei-Feng Lin. Music, heart rate variability, and symptom clusters: a comparative study. Supportive care in cancer. 2020; 28 (1): 351–360. DOI: 10.1007/ s00520-019-04817-x

  56. Tkachenko G.A., Vorotnikov I.K., Buydenok Yu. V. Rol' psikhoterapii v lechenii bol'nykh rakom molochnoy zhelezy [Psychotherapy in treatment of patients with breast cancer]. Vestnik «RONTs im. N.N. Blokhina» RAMN. 2010; 21 (3): 61–64 (in Russian).

  57. Chih-Yuan Chuang, Wei-Ru Han, Pei-Chun Li, Mi-Yun Song, Shuenn-Tsong Young. Effect of long-term music therapy intervention on autonomic function in anthracycline-treated breast cancer patients. Integrative cancer therapies. 2011; 10 (4): 312–316. DOI: 10.1177/1534735411400311.

  58. Tkachenko G.A., Safronova L.V. Ispol'zovanie simvol dramy v psikhoterapii onkologicheskikh bol'nykh [Symbol of drama in the psychotherapy of cancer patients]. Sbornik konferentsiy NITs Sotsiosfera. 2011; 18: 82–87 (in Russian).

  59. Olsson Möller U., Beck I., Rydén L., Malmström M. A comprehensive approach to rehabilitation interventions following breast cancer treatment – a systematic review of systematic reviews. BMC Cancer. 2019; 19 (1): 472. DOI: 10.1186/s12885-019-5648-7.

  60. Grant A. McCallum, Jay Shiralkar, Diana Suchiu, Gil Covarrubias, Jennifer S.Yu, Efstathios Karathanasis, Dominique M. Durand. Chronic neural activity recorded within breast tumors. Scientific reports. 2020; 10 (1): 14824. DOI: 10.1038/s41598-020-71670-y.

Received Jul 13, 2021; accepted October 08, 2021.

 

Information about the authors

Udalov Yuriy Dmitrievich, Doctor of Sciences (Medicine), Deputy Director General, Federal Scientific Clinical Centre for Medical Radiology and Oncology, Federal Medical and Biological Agency. 433507, Russia, Ulyanovsk region, Dimitrovgrad, Kurchatov St., 5B; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0002-9739-8478

Belova Lyudmila Anatol'evna, Doctor of Sciences (Medicine), Professor, Chair of Neurology, Neurosurgery and Medical Rehabilitation, Ulyanovsk State University. 432017, Russia, Ulyanovsk, L. Tolstoy St., 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0002-9585-5604

Mashin Viktor Vladimirovich, Doctor of Sciences (Medicine), Professor, Cheir of Neurology, Neurosurgery and Medical Rehabilitation, Ulyanovsk State University. 432017, Russia, Ulyanovsk, L. Tolstoy St., 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0003-0085-3727

Danilova Lyudmila Alekseevna, Candidate of Sciences (Medicine), Federal Scientific Clinical Centre for Medical Radiology and Oncology, Federal Medical and Biological Agency. 433507, Russia, Ulyanovsk region, Dimitrovgrad, Kurchatov St., 5B; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0001-8308-9837

Kuvayskaya Anastasiya Andreevna, Resident, Chair of Neurology, Neurosurgery and Medical Rehabilitation, Ulyanovsk State University. 432017, Russia, Ulyanovsk, L. Tolstoy St., 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0002-2998-4344

 

For citation

Udalov Yu.D., Belova L.A., Mashin V.V., Danilova L.A., Kuvayskaya A.A. Porazhenie vegetativnoy nervnoy sistemy u bol'nykh rakom molochnoy zhelezy [Autonomic nervous system dysfunction in breast cancer patients]. Ul'yanovskiy mediko-biologicheskiy zhurnal. 2021; 4: 73–88. DOI: 10.34014/2227-1848-2021-4-73-88 (in Russian).

 

Скачать статью

УДК 616.839+616-006.66

DOI 10.34014/2227-1848-2021-4-73-88

 

ПОРАЖЕНИЕ ВЕГЕТАТИВНОЙ НЕРВНОЙ СИСТЕМЫ У БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ

Ю.Д. Удалов1, Л.А. Белова2, В.В. Машин2, Л.А. Данилова1, А.А. Кувайская2

1 ФГБУ «Федеральный научно-клинический центр медицинской радиологии и онкологии» Федерального медико-биологического агентства, г. Димитровград, Россия;

2 ФГБОУ ВО «Ульяновский государственный университет», г. Ульяновск, Россия

 

При изучении онкологического заболевания необходимо не только оценивать его характер, течение и исход в зависимости от локального процесса, но и учитывать общее состояние организма, так как множественное поражение органов имеет прогностическое значение и определяет исход заболевания. Следует рассматривать все механизмы и структуры, которые оказывают интегративное и гомеостатическое действие на организм в целом. Одной из таких структур является вегетативная нервная система.

Традиционно вегетативная нервная система рассматривалась в аспекте 3 составляющих: симпатической, парасимпатической и кишечной. Однако в последнее время на первый план вышли представления о нейроэндокринных и нейроиммунных системах, обосновывающие расширение значения понятия «автономность нервной системы». При поражении автономной нервной системы возникает дисрегуляция непроизвольных функций организма, развивается автономная нейропатия. Выделяют кардиоваскулярную, гастроинтестинальную, урогенитальную, судомоторную формы автономной нейропатии, которые характеризуются определенными изменениями при различных патологических состояниях организма, особенно при злокачественных процессах. Фокус нашего научного внимания был направлен на рак молочной железы, который занимает первое место в структуре онкологических заболеваний в Российской Федерации.

В литературе представлены немногочисленные исследования, отражающие изменения состояния вегетативной нервной системы у больных раком молочной железы в процессе противоопухолевой лекарственной терапии с учётом характера течения и клинических особенностей болезни, а также методы рациональной коррекции её дисфункции.

В статье приведен анализ ряда научных источников, которые могут помочь в исследовании различных форм автономной нейропатии у больных раком молочной железы и позволят оценить возможность применения медицинской реабилитации для данной категории пациентов.

Ключевые слова: вегетативная (автономная) нервная система, автономная нейропатия, рак молочной железы, противоопухолевая лекарственная терапия.

 

Литература

  1. Erica A. Wehrwein, Hakan S. Orer, Susan M. Barman. Overview of the Anatomy, Physiology, and Pharmacology of the Autonomic Nervous System. Comprehensive Physiology. 2016; 6 (3): 1239–1278. DOI: 10.1002/cphy.c150037.

  2. Goldstein D.S. The extended autonomic system, dyshomeostasis, and COVID-19. Clinical autonomic research: official journal of the Clinical Autonomic Research Society. 2020; 30 (4): 299–315.

  3. Dineen J., Freeman R. Autonomic Neuropathy. Seminars in neurology. 2015; 35 (4): 458–468. DOI: 10.1055/s-0035-1558983.

  4. Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Вып. 9 (доп.). Сахарный диабет. 2019; 22 (S1): 104–106. DOI: 10.14341/DM221S1.

  5. Koual M., Tomkiewicz С., Cano-Sancho German, Antignac Jean-Philippe, Bats Anne-Sophie, Coumoul X. Environmental chemicals, breast cancer progression and drug resistance. Environ. Health. 2020; 19 (1): 117. DOI: 10.1186/s12940-020-00670-2.

  6. Агеева Л.И., Александрова Г.А., Зайченко Н.М. Здравоохранение в России. 2019: стат. сб. Москва; 2019.

  7. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019.

  8. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2018 году (заболеваемость и смертность). Москва: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019.

  9. Susan G. Lakoski, Lee W. Jones, Ronald J. Krone, Phyllis K. Stein, Jessica M. Scott. Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. American heart journal. 2015; 170 (2): 231–241. DOI: 10.1016/j.ahj.2015.05.014.

  10. Guy Jerusalem, Patrizio Lancellotti, Sung-Bae Kim. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast cancer research and treatment. 2019; 177 (2): 237–250. DOI: 10.1007/s10549-019-05303-y.

  11. Rodrigo Carrasco, Rodrigo L Castillo, Juan G Gormaz, Montserrat Carrillo, Paaladinesh Thavendiranathan. Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies. Oxidative medicine and cellular longevity. 2021; 2021: 1–2. DOI: 10.1155/2021/8863789.

  12. Adão R.G. de Keulenaer, Leite-Moreira A., Brás-Silva C. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention. Revista Portuguesa de Cardiologia. 2013; 32 (5): 395–409. DOI: 10.1016/j.repc.2012.11.002.

  13. Emanuela Salvatorelli, Pierantonio Menna, Massimo Chello, Elvio Covino, Giorgio Minotti. Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites. Journal of Pharmacology and Experimental Therapeutics. 2018; 364 (2): 323–331. DOI: 10.1124/jpet.117.246140.

  14. Lakoski S.G., Jones L.W., Krone R.J., Stein P.K., Scott J.M. Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. American heart journal. 2015; 170 (2): 231–241.

  15. Kirkham А.A, Lloyd M.G., Claydon V.E, Gelmon K.A., McKenzie D.C., Campbell K.L. Longitudinal Study of the Association of Clinical Indices of Cardiovascular Autonomic Function with Breast Cancer Treatment and Exercise Training. The Oncologist. 2019; 24 (2): 273–284. DOI: 10.1634/theoncologist.2018-0049.

  16. Peter A. Henriksen. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart (British Cardiac Society). 2018; 104 (12): 971–977. DOI: 10.1136/heartjnl-2017-312103.

  17. Jones L.W., Courneya K.S., Mackey J.R., Muss H.B., Pituskin E.N., Scott J.M., Hornsby W.E., Coan A.D., Herndon 2nd J.E., Douglas P.S., Haykowsky M. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. Journal of clinical oncology. 2012; 30 (20): 2530–2537. DOI: 10.1200/JCO.2011.39.9014.

  18. Kluser Sales A.R., Negrão M.V., Testa L., Ferreira-Santos L., Ramalho Groehs R.V., Carvalho B., Toschi-Dias E., Rocha N.G., Martins Laurindo F.R., Debbas V., Rondon M.U.PB., Mano M.S., Hajjar L.A., Gehm Hoff P.M., Filho R.K., Negrão C.E. Chemotherapy acutely impairs neurovascular and hemodynamic responses in women with breast cancer. American journal of physiology. Heart and circulatory physiology. 2019; 317 (7): 1–12. DOI: 10.1152/ajpheart.00756.2018.

  19. Sarita Lígia Pessoa de Melo Machado Guimarães, Simone Cristina Soares Brandão, Luciana Raposo Andradе, Rafael José Coelho Maia, Brivaldo Markman Filho. Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity. Arquivos Brasileiros de Cardiologia. 2015; 105 (3): 228–34. DOI: 10.5935/abc.20150075.

  20. Акарачкова Е.С., Байдаулетова А.И., Беляев А.А., Блинов Д.В, Громова О.А., Дулаева М.С., Замерград М.В., Исайкин А.И., Кадырова Л.Р., Клименко А.А., Кондрашов А.А., Косивцова О.В., Котова О.В., Лебедева Д.И., Медведев В.Э., Орлова А.С., Травникова Е.В., Яковлев О.Н. Стресс: причины и последствия, лечение и профилактика. Клинические рекомендации. СПб.: Скифия-принт; М.: Профмедпресс; 2020.

  21. Киселева М.Г. Психологические факторы и течение сердечно-сосудистых заболеваний. Научный психологический журнал. 2012; 1 (7): 124–130.

  22. Зикиряходжаев А.Д., Ермощенкова М.В., Сирота Н.А., Фетисов Б.А. Психологические аспекты больных раком молочной железы в зависимости от наличия видимого послеоперационного дефекта. Исследования и практика в медицине. 2015; 2 (2): 85–91. DOI: 10.17709/2409-2231-2015-2-2-85-91.

  23. Удалов Ю.Д., Гордиенко А.В., Самойлов А.С., Бахарев С.А. Прогнозирование и минимизация рисков фатальных исходов планового хирургического лечения онкологических больных с коморбидной соматической патологией. Медицина экстремальных ситуаций. 2018; 20 (2): 136–145.

  24. Колотик-Каменева О.Ю., Белова Л.А., Машин В.В. Эмоционально-волевые нарушения как результат церебрального сосудистого ремоделирования при гипертонической болезни. Ульяновский медико-биологический журнал. 2015; 4: 54–57.

  25. Снеговой А.В., Давыдов М.И. Современные возможности поддерживающей терапии лекарственного противоопухолевого лечения. Вестник ФГБУ «РОНЦ им. Н.Н. Блохина». 2016; 27 (2): 5–16.

  26. Титова Ж.В., Бодиенкова Г.М. Роль цитокиновой сети в механизмах нейроиммунного взаимодействия (обзор литературы). Бюллетень ВСНЦ СО РАМН. 2013; 2–1 (90): 171–175.

  27. Haworth K.B., Leddon J.L., Chen C.Y., Horwitz E.M., Mackall C.L., Cripe T.P. Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr. Blood Cancer. 2015; 62 (4): 571–576. DOI: 10.1002/pbc.25359.

  28. Quezada S.A., Peggs K.S. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. British journal of Сancer. 2013; 108 (8): 1560–1565. DOI: 10.1038/bjc.2013.117.

  29. Mittendorf E., Philips A., Meric-Bernstam F., Qiao N., Wu Y., Harrington S., Su X., Wang Y., Gonzalez-Angulo A.M., Akcakanat A., Chawla A., Curran M., Hwu P., Sharma P., Litton J.K., Molldrem J.J., Alatrash G. PD-L1 expression in triple negative breast cancer. Cancer immunology research. 2014; 2: 361–370.

  30. Denkert C., Liedtke C., Tutt A., von Minckwitz G. Молекулярные изменения при тройном негативном раке молочной железы – путь к новым стратегиям лечения. Lancet. 2017; 389 (10087): 2430–2442. DOI: 10.1016/S0140-6736(16)32454-0.

  31. Gobbini E., Ezzalfani M., Dieras V., Bachelot T., Brain E., Debled M., Jacot W., Mouret-Reynier M.A., Goncalves A., Dalenc F., Patsouris A., Ferrero J.M., Levy C., Lorgis V., Vanlemmens L., Lefeuvre Plesse C., Mathoulin-Pelissier S., Petit T., Uwer L., Jouannaud C., Leheurteur M., Lacroix-Triki M., Cleaud A.L., Robain M., Courtinard C., Cailliot C., Perol D., Delaloge S. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European journal of cancer. 2018; 96: 17–24. DOI: 10.1016/j.ejca.2018.03.015.

  32. Irwin M.R., Cole S.W. Reciprocal regulation of the neural and innate immune systems. Nature Reviews Immunology. 2011; 11: 625–632.

  33. Howard-Anderson J., Ganz P.A., Bower J.E., Stanton A.L. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. Journal of the National Cancer Institute. 2012; 104: 386–405.

  34. Alexandra D. Crosswell, Kimberly G. Lockwood, Patricia A. Ganz, Bower J.E. Low heart rate variability and cancer-related fatigue in breast cancer survivors. Psychoneuroendocrinology. 2014; 45: 58–66. DOI: 10.1016/j.psyneuen.2014.03.011.

  35. Allison Soucise, Caila Vaughn, Cheryl L. Thompson. Sleep quality, duration, and breast cancer aggressiveness. Breast cancer research and treatment. 2017; 164 (1): 169–178. DOI: 10.1007/s10549-017-4245-1.

  36. Otte J.L., Davis L., Carpenter J.S., Krier C., Skaar T.C., Rand K.L., Weaver M., Landis C., Chernyak Y., Manchanda S. Sleep disorders in breast cancer survivors. Supportive care in cancer. 2016; 24: 4197–4205. DOI: 10.1007/s00520-016-3247-6.

  37. Otte J.L., Carpenter J.S., Russell K.M., Bigatti S., Champion V.L. Prevalence, severity, and correlates of sleep-wake disturbances in long-term breast cancer survivors. Journal of pain and symptom management. 2010; 39 (3): 535–547. DOI: 10.1016/j.jpainsymman.2009.07.004.

  38. Borniger J.C. Central Regulation of Breast Cancer Growth and Metastasis. Journal of cancer metastasis and treatment. 2019; 5: 23. DOI: 10.20517/2394-4722.2018.107.

  39. Hanahan D., Weinberg R.A. Hallmarks of Cancer: The Next Generation. Journal of cancer metastasis and treatment. 2011; 144: 646–674. DOI: 10.1016/j.cell.2011.02.013.

  40. Palesh O.G., Roscoe J.A., Mustian K.M., Roth T., Savard J., Ancoli-Israel S., Heckler C., Purnell J.Q., Janelsins M.C., Morrow G.R. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. Journal of Сlinical Оncology. 2010; 28 (2): 292–298. DOI: 10.1200/JCO.2009.22.5011.

  41. Palesh O., Aldridge-Gerry A., Zeitzer J.M., Koopman C., Neri E., Giese-Davis J., Jo B., Kraemer H., Nouriani B., Spiegel D. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep. 2014; 37 (5): 837–842. DOI: 10.5665/sleep.3642.

  42. Bower J.E., Ganz P.A., Irwin M.R., Kwan L., Breen E.C., Cole S.W. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? Journal of Сlinical Оncology. 2011; 29 (26): 3517–3522. DOI: 10.1200/JCO.2011.36.1154.

  43. Bower J.E., Lamkin D.M. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain, behavior, and immunity. 2013; 30 Suppl. (0): 48–57. DOI: 10.1016/ j.bbi.2012.06.011.

  44. Liu L., Mills P.J., Rissling M., Fiorentino L., Natarajan L., Dimsdale J.E., Sadler G.R., Parker B.A., Ancoli-Israe S. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain, behavior, and immunity. 2012; 26 (5): 706–713. DOI: 10.1016/j.bbi.2012.02.001.

  45. Krueger J.M., Frank M.G., Wisor J.P., Roy S. Review Sleep function: Toward elucidating an enigma. Sleep Medicine Reviews. 2016; 28: 46–54. DOI: 10.1016/j.smrv.2015.08.005.

  46. Schmidt E.M., Linz B., Diekelmann S., Besedovsky L., Lange T., Born J. Effects of an interleukin-1 receptor antagonist on human sleep, sleep-associated memory consolidation, and blood monocytes. Brain, behavior, and immunity. 2015; 47: 178–185. DOI: 10.1016/j.bbi.2014.11.012.

  47. Savard J., Ivers H., Villa J., Caplette-Gingras A., Morin C.M. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. Journal of Сlinical Оncology. 2011; 29 (26): 3580–3586. DOI: 10.1200/JCO.2010.33.2247. 

  48. Scott J.M., Jones L.W., Hornsby W.E., Koelwyn G.J., Khouri M.G., Joy A.A., Douglas P.S., Lakoski S.G. Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training. International Journal of Сardiology. 2014; 171 (2).

  49. Удалов Ю.Д., Белова Л.А., Машин В.В., Степанюченко Е.М., Данилова Л.А., Айзатуллин И.Ф., Кувайская А.А. Методические основы онкореабилитации на базе ФГБУ ФНКЦРиО ФМБА России. Методические рекомендации. Москва; 2021: 26–56.

  50. Lakoski S.G., Jones L.W., Krone R.J., Stein P.K., Scott J.M. Autonomic dysfunction in early breast cancer: Incidence, clinical importance, and underlying mechanisms. American heart journal. 2015; 170: 231–241.

  51. Niederer D., Vogt L., Thiel C., Schmidt K., Bernhörster M., Lungwitz A., Jäger E., Banzer W. Exercise effects on HRV in cancer patients. International Journal of Sports Medicine. 2013; 34: 68–73.

  52. Hyeng-Cheol Shin, Jung-Ok Yang, Seung-Ryol Kim. Effects of circuit exercise on autonomic nerve system of survivors after surgery of breast cancer. Journal of physical therapy science. 2016; 28 (10): 2898–2903. DOI: 10.1589/jpts.28.2898.

  53. Toohey K., Pumpa К., McKune A., Cooke J., Welvaert M., Northey J., Quinlan C., Semple S. The impact of high-intensity interval training exercise on breast cancer survivors: a pilot study to explore fitness, cardiac regulation and biomarkers of the stress systems. BMC Cancer. 2020; 20 (1): 787. DOI: 10.1186/s12885-020-07295-1.

  54. Palesh O., Aldridge-Gerry A., Zeitzer J.M., Koopman C., Neri E., Giese-Davis J., Jo B., Kraemer H., Nouriani B., Spiegel D. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep. 2014; 37 (5): 837–842. DOI: 10.5665/sleep.3642.

  55. Shu-Chuan Chen, Ming-Lee Yeh, Hsiu-Ju Chang, Mei-Feng Lin. Music, heart rate variability, and symptom clusters: a comparative study. Supportive care in cancer. 2020; 28 (1): 351–360. DOI: 10.1007/ s00520-019-04817-x.

  56. Ткаченко Г.А., Воротников И.К., Буйденок Ю. В. Роль психотерапии в лечении больных раком молочной железы. Вестник «РОНЦ им. Н.Н. Блохина» РАМН. 2010; 21 (3): 61–64.

  57. Chih-Yuan Chuang, Wei-Ru Han, Pei-Chun Li, Mi-Yun Song, Shuenn-Tsong Young. Effect of long-term music therapy intervention on autonomic function in anthracycline-treated breast cancer patients. Integrative cancer therapies. 2011; 10 (4): 312–316. DOI: 10.1177/1534735411400311.

  58. Ткаченко Г.А., Сафронова Л.В. Использование символ драмы в психотерапии онкологических больных. Сборник конференций НИЦ Социосфера. 2011; 18: 82–87.

  59. Olsson Möller U., Beck I., Rydén L., Malmström M. A comprehensive approach to rehabilitation interventions following breast cancer treatment – a systematic review of systematic reviews. BMC Cancer. 2019; 19 (1): 472. DOI: 10.1186/s12885-019-5648-7.

  60. Grant A. McCallum, Jay Shiralkar, Diana Suchiu, Gil Covarrubias, Jennifer S.Yu, Efstathios Karathanasis, Dominique M. Durand. Chronic neural activity recorded within breast tumors. Scientific reports. 2020; 10 (1): 14824. DOI: 10.1038/s41598-020-71670-y.

Поступила в редакцию 13.07.2021; принята 08.10.2021.

 

Авторский коллектив

Удалов Юрий Дмитриевич – доктор медицинских наук, и.о. генерального директора, ФГБУ «Федеральный научно-клинический центр медицинской радиологии и онкологии» Федерального медико-биологического агентства. 433507, Россия, Ульяновская область, г. Димитровград, ул. Курчатова, 5В; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0002-9739-8478

Белова Людмила Анатольевна – доктор медицинских наук, профессор кафедры неврологии, нейрохирургии и медицинской реабилитации, ФГБОУ ВО «Ульяновский государственный университет». 432017, Россия, г. Ульяновск, ул. Л. Толстого, 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0002-9585-5604

Машин Виктор Владимирович – доктор медицинских наук, профессор кафедры неврологии, нейрохирургии и медицинской реабилитации, ФГБОУ ВО «Ульяновский государственный университет». 432017, Россия, г. Ульяновск, ул. Л. Толстого, 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0003-0085-3727

Данилова Людмила Алексеевна – кандидат медицинских наук, ФГБУ «Федеральный научно-клинический центр медицинской радиологии и онкологии» Федерального медико-биологического агентства. 433507, Россия, Ульяновская область, г. Димитровград, ул. Курчатова, 5В; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0001-8308-9837

Кувайская Анастасия Андреевна – ординатор кафедры неврологии, нейрохирургии и медицинской реабилитации, ФГБОУ ВО «Ульяновский государственный университет». 432017, Россия, г. Ульяновск, ул. Л. Толстого, 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0002-2998-4344

 

Образец цитирования

Удалов Ю.Д., Белова Л.А., Машин В.В., Данилова Л.А., Кувайская А.А. Поражение вегетативной нервной системы у больных раком молочной железы. Ульяновский медико-биологический журнал. 2021; 4: 73–88. DOI: 10.34014/2227-1848-2021-4-73-88.